Oncology and Hematology - MedEd On The Go

Episodes 65-80 of 113

Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
MinuteCE®
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
1.00 program credit
- Charu Aggarwal, MD, MPH
- Alexander Drilon, MD
1.00 program credit
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
MinuteCE®
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
1.00 program credit
- Sagar Lonial, MD, FACP
- Caitlin Costello, MD
1.00 program credit
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
MinuteCE®
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
MinuteCE®
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
MinuteCE®
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
MinuteCE®
Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies
1.25 credits 11 episodes
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 credits 11 episodes
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
MinuteCE®
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
MinuteCE®
RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
0.75 program credits
- Christopher M. Gallagher, MD
0.75 program credits
Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
MinuteCE®
Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
0.75 program credits
- Adam Brufsky, MD, PhD
- Christopher M. Gallagher, MD
0.75 program credits
Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
MinuteCE®
Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
0.75 program credits
- Adam Brufsky, MD, PhD
0.75 program credits
Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
MinuteCE®
Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
0.75 program credits
- Christopher M. Gallagher, MD
- Adam Brufsky, MD, PhD
0.75 program credits
Importance of the Patient Perspective on RWE in Formulating SDM Conversations
Importance of the Patient Perspective on RWE in Formulating SDM Conversations
MinuteCE®
Importance of the Patient Perspective on RWE in Formulating SDM Conversations
0.75 program credits
- Adam Brufsky, MD, PhD
- Christopher M. Gallagher, MD
0.75 program credits
MinuteCE®
RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer
0.75 credits 7 episodes
- Adam Brufsky, MD, PhD
- Christopher M. Gallagher, MD
0.75 credits 7 episodes
Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
MinuteCE®
Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
0.75 program credits
- Christopher M. Gallagher, MD
0.75 program credits

5/8